(Q45405108)

English

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

scientific article published in April 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial (English)

1 reference

Europe PubMed Central

14 December 2017

phase II clinical trial

0 references

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Christine Katlama

3

object named as

Christine Katlama

0 references

Adriano Lazzarin

object named as

Adriano Lazzarin

5

0 references

Beatriz Grinsztejn

1

object named as

Beatriz Grinsztejn

1 reference

Europe PubMed Central

14 December 2017

author name string

Bach-Yen Nguyen

2

1 reference

Europe PubMed Central

14 December 2017

Jose M Gatell

4

1 reference

Europe PubMed Central

14 December 2017

Daniel Vittecoq

6

1 reference

Europe PubMed Central

14 December 2017

Charles J Gonzalez

7

1 reference

Europe PubMed Central

14 December 2017

Joshua Chen

8

1 reference

Europe PubMed Central

14 December 2017

Charlotte M Harvey

9

1 reference

Europe PubMed Central

14 December 2017

Robin D Isaacs

10

1 reference

Europe PubMed Central

14 December 2017

Protocol 005 Team

11

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

1 April 2007

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

369

1 reference

Europe PubMed Central

14 December 2017

1261-1269

1 reference

Europe PubMed Central

14 December 2017

9569

1 reference

Europe PubMed Central

14 December 2017

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of drug resistance on viral load in patients failing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960597-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)60597-2

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45405108&oldid=2076646236"